Send to

Choose Destination
Curr Oncol. 2009 Aug;16(4):61-6.

RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges.

Author information

Goodman Cancer Centre, Department of Biochemistry, McGill University, 1160 Avenue des Pins West, Montreal, Quebec H3A 1A3.


The discovery that RNA interference (RNAi) and its functional derivatives, small interfering RNAs (SiRNAs) and micro-RNAs (MiRNAs) could mediate potent and specific gene silencing has raised high hopes for cancer therapeutics. The prevalence of these small (18-25 nucleotide) non-coding rnas in human gene networks, coupled with their unique specificity, has paved the way for the development of new and promising therapeutic strategies in re-directing or inhibiting small rna phenomena.Three strategies are currently being developed: De novo RNAi programming using synthetic SiRNAS to target the expression of genes. Strengthening or recapitulation of the physiologic targeting of messenger RNAs by specific MiRNAs. Sequence-specific inhibition of Mi RNA functions by nucleic acid analogs. Each strategy, currently being developed both in academia and in industry, holds promise in cancer therapeutics.


Cancer therapy; mirna; nucleic acid analogs; oncomirs; rnai therapy; sirna; tumour-suppressor mirnas

Supplemental Content

Full text links

Icon for Multimed Inc. Icon for PubMed Central
Loading ...
Support Center